Biomedica Italia is pleased to announce the expansion of its long-standing partnership with Bioventus, a leading medical technology company, with the addition of Durolane to its portfolio of products distributed in Italy.

Durolane is a hyaluronic acid injection therapy indicated for the treatment of joint osteoarthritis. Hyaluronic acid is a natural component of the joints that plays a key role in lubricating and nourishing cartilage.

“We are excited to expand our partnership with Bioventus to distribute Durolane in Italy. Durolane is an innovative and proven therapy that is a valuable addition to our portfolio of products. We are confident that this collaboration will further contribute to improving the care of patients with this disease in Italy.” – said Alessandro Saccone Sales & Marketing Director of Biomedica Italia.

The collaboration between Biomedica Italia and Bioventus is built on shared values of excellence, innovation, and a commitment to improving patient care quality.

Go to the product page.